University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Charts & Tables
Antiretroviral Management Charts and Tables
gray line
Special Situations
Dosing of Antiretroviral Drugs in Adults with Chronic Kidney Disease and Hemodialysis
Ian R. McNicholl, PharmD, BCPS, and Rudolph A. Rodriguez, MD, University of California San Francisco. Updated October 2012.
Dosing for Ritonavir-Boosted Protease Inhibitors
Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated July 2010.
Adverse Effects
Adverse Effects of Antiretroviral Drugs
Ian McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.
Adverse Events Due to Nonantiretroviral Medications during Treatment of HIV-Related Infections and Complications
Ian McNicholl, PharmD, BCPS, and Christine Jamjian, PharmD, University of California San Francisco. Updated October 2012.
Adverse Effects of Antiretroviral Agents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Drug Characteristics
Antiretroviral Drug Profiles
Susa Coffey, MD. University of California San Francisco.
Currently Approved Drugs for HIV: A Comparative Chart
AIDSmeds.com. Table showing standard antiretroviral dosages, plus dosing and side effect considerations and links to in-depth drug monographs.
Drug Interactions
ARV Interactions with HCV Serine Protease Inhibitors
Susa Coffey, MD, and Annie Luetkemeyer, MD, University of California San Francisco. Updated January 2013.
Database of Antiretroviral Drug Interactions
HIV InSIte, Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Create custom reports with this interactive tool.
Dosage Adjustments for ARV-ARV Drug Interactions
Susa Coffey, MD, and Ian R. McNicholl, PharmD, BCPS, University of California San Francisco. Updated October 2012.
Drugs That Should Not Be Used With Antiretroviral Agents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Etravirine-ARV Interactions
Susa Coffey, MD, HIV InSite Medical Editor; Ian R. McNicholl, PharmD, HIV InSite Pharmacy Editor. Updated July 2011. Reference table to help clinicians navigate the complexities of drug interactions with this NNRTI.
Interactions between ARVs and Statin Medications: Recommendations for Coadministration
Susa Coffey, MD, HIV InSite Medical Editor. Updated October 2012.
Recreational Drugs and HIV Antivirals: A Guide to Interactions for Clinicians
Christine Kubin, PharmD, and Antonio Urbina, MD, New York/New Jersey AIDS Education and Training Center. 2008. Contains information on interactions with alcohol, street drugs, and erectile dysfunction agents.
Regimen Selection / Treatment Strategy
Summary tables from the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Panel on Antiretroviral Guidelines for Adult and Adolescents. U.S. Department of Health and Human Services.
What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient
Recommended, Alternative, and Other Antiretroviral Regimen Options for Treatment-Naive Patients (Table 6)
ARV Components or Regimens Not Recommended as Initial Therapy (Table 9)
ARV Regimens or Components That Should Not Be Offered at Any Time (Table 10)
Access Information
FDA-Approved and Investigational Antiretrovirals
HIV InSite. Comprehensive chart of FDA-approved and experimental drugs.
Expanded Access, Compassionate Use, and Treatment IND Programs
HIV InSite. Listing of programs that provide patients with limited access to promising experimental treatments before the medications have been given full approval by the U.S. Food and Drug Administration. November 2007.
Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan (PEPFAR)
U.S. Food and Drug Administration. Table detailing FDA approvals as part of a special initative for granting approval to manufacturers of generic antiretrovirals so that these drugs may be purchased for use outside the U.S. and paid for with PEPFAR funding.